Predict Health Risks Before They Escalate

We're not an AI company or a software company—we believe the best healthcare breakthroughs come from applying real science to generate actionable insights.

Burak Multiomics uses multi-omics velocity analysis to trace disease earlier & enable preventive interventions.

See How It Works

Burak Multiomics Analyzes

Gut Gut Fragmented biomarker data weeks early
Blood Blood Delayed disease detection risk multiplier
Inflammation Inflammation High inflammatory amplifier 3-of-5 signal confidence

We connect what your gut is already saying, the story in your blood, and the signal of inflammation; so you see the full picture before it becomes a crisis.

Why Burak Multiomics Works

Disease develops gradually through measurable biological changes. Our multi-omics approach detects these signals early to enable preventive healthcare decisions.

Multi-Omics Integration
Block 1 - Multi-Omics Integration

Burak Multiomics combines gut microbiome, blood biomarkers, and inflammatory markers to create a comprehensive view of biological health.

Velocity-Based Analysis
Block 2 - Velocity-Based Analysis

Instead of isolated readings, Burak Multiomics analyzes how quickly biological markers change over time, revealing hidden early-risk patterns.

Early Predictive Detection
Block 3 - Early Predictive Detection

By identifying risk signals weeks before symptoms appear, Burak Multiomics supports timely clinical and lifestyle interventions.

Validation & Impact

Peer-reviewed methodology, a proven predictive window, and measurable institutional ROI—not claims, but results.

✓

Peer-Reviewed Science

Our methodology and AMS module were peer-reviewed and showcased at the 7th International Qatar Pharmacy Conference (QIPC) 2026. Regression tests on 500 reports showed 94% predictive accuracy.

⏱

The 8-Week Predictive Window

We calculate the Velocity of Failure (ΔV) between gut and blood markers to predict metabolic collapse up to 8 weeks before clinical manifestation—validated in ischemic gangrene and T5 Diabetes cohorts.

Institutional ROI

Estimated $142,500 savings per batch (500 reports). For a full-risk cohort, the model projects $150M+ USD annual cost-avoidance potential by preventing high-cost states before they occur.

Ecosystem & Partners

Semifinalist in GCC Eureka

GCC Eureka is a flagship innovation program that brings together startups, corporates, and government entities across the Gulf Cooperation Council to accelerate high-impact solutions. Being selected as a semifinalist recognizes Burak Multiomics as one of the region’s most promising ventures in health tech and predictive analytics.

Eureka! GCC

Continuous Research Pipeline

Data Collection
Pre-clinical Trials
Ongoing Studies
Pilot of Validation
Deployment
Optimization

Frequently Asked Questions

What is Burak Multiomics? +

Burak Multiomics is a data integration and analytics platform designed to unify multi-omics datasets — including genomics, transcriptomics, proteomics, and metabolomics — into a single, interpretable system.

It enables researchers and clinicians to transform complex biological data into actionable insights across both clinical and population-level use cases.

What problem does Burak Multiomics solve? +

Multi-omics data is often fragmented across tools, difficult to standardize, and challenging to interpret in a clinical context.

Burak solves this by integrating multiple biological layers into a unified framework, reducing data silos and enabling cross-layer analysis that supports precision medicine and large-scale research initiatives.

Who is Burak Multiomics built for? +

Burak Multiomics is designed for:

  • Clinical researchers
  • Translational scientists
  • Precision medicine teams
  • Biotech and pharmaceutical organizations
  • Population health researchers

It supports teams that need scalable, structured, and interpretable multi-omics analysis.

How does Burak Multiomics support clinical and population insights? +

Burak operates through structured analytical layers:

  • Clinical Layer: Connects molecular data to disease pathways, biomarkers, and potential therapeutic relevance.
  • Population Layer: Identifies cohort-level trends, stratifies patient groups, and enables large-scale biological pattern discovery.

This layered approach allows users to move from individual molecular signals to broader population-level understanding.

How is Burak Multiomics different from traditional bioinformatics tools? +

Traditional bioinformatics tools often focus on single-omics analysis or require heavy technical expertise to integrate multiple datasets.

Burak Multiomics is designed as an integrated platform that:

  • Unifies multiple biological data types
  • Enables cross-layer exploration
  • Improves interpretability
  • Scales from individual cases to large cohorts

It bridges the gap between raw omics data and real-world clinical or research decisions.